The analyst rating for JD HEALTH (06618.HK) is a "Buy," as reiterated by BofA Securities. This rating is based on the company's full-year revenue growth of 26% YoY, which exceeded market expectations, and an adjusted net profit that also surpassed forecasts. Additionally, BofA Securities has raised its revenue growth forecast for 2026 from 16% to 18%, reflecting confidence in the company's accelerated growth in the pharmaceutical category. Despite maintaining a conservative outlook on profit margins due to anticipated investments and lower interest income, the overall positive performance and growth prospects support the Buy rating.
